D. Tural Et Al. , "Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS," TUMOR BIOLOGY , vol.35, no.2, pp.1041-1049, 2014
Tural, D. Et Al. 2014. Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS. TUMOR BIOLOGY , vol.35, no.2 , 1041-1049.
Tural, D., Batur, S., Erdamar, S., Akar, E., Kepil, N., Mandel, N. M., ... Serdengecti, S.(2014). Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS. TUMOR BIOLOGY , vol.35, no.2, 1041-1049.
Tural, Deniz Et Al. "Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS," TUMOR BIOLOGY , vol.35, no.2, 1041-1049, 2014
Tural, Deniz Et Al. "Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS." TUMOR BIOLOGY , vol.35, no.2, pp.1041-1049, 2014
Tural, D. Et Al. (2014) . "Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS." TUMOR BIOLOGY , vol.35, no.2, pp.1041-1049.
@article{article, author={Deniz TURAL Et Al. }, title={Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS}, journal={TUMOR BIOLOGY}, year=2014, pages={1041-1049} }